MCID: MLG108
MIFTS: 67

Malignant Melanoma, Somatic malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Eye diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Malignant Melanoma, Somatic

About this section

Aliases & Descriptions for Malignant Melanoma, Somatic:

Name: Malignant Melanoma, Somatic 52 24
Melanoma 11 27 50 38 39 13 68
Malignant Melanoma 11 27 13
Familial Melanoma 11 54 13
Familial Atypical Multiple Mole Melanoma Syndrome 24 54
Melanoma-Pancreatic Cancer Syndrome 54 68
Dysplastic Nevus Syndrome 24 68
Cutaneous Melanoma 24 68
Familial Atypical Multiple Mole Melanoma-Pancreatic Carcinoma Syndrome 54
Familial Atypical Multiple Mole-Melanoma 68
Familial Atypical Mole Melanoma Syndrome 68
Familial Atypical Multiple Mole Melanoma 50
Familial Dysplastic Nevus Syndrome 54
Melanoma, Cutaneous Malignant, 1 12
 
Familial Atypical Mole Syndrome 54
Cutaneous Malignant Melanoma 1 27
Familial Clark Nevus Syndrome 54
Melanoma, Malignant, Somatic 12
Cutaneous Malignant Melanoma 24
Hereditary Melanoma 68
Melanoma, Familial 48
B-K Mole Syndrome 54
Famm-Pc Syndrome 54
Naevocarcinoma 11
Fammm Syndrome 54
Fammm 24
Cmm 24

Characteristics:

Orphanet epidemiological data:

54
familial melanoma:
Inheritance: Autosomal dominant,Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: Adult
familial atypical multiple mole melanoma syndrome:
Inheritance: Autosomal dominant; Age of onset: Adolescent,Adult,Childhood; Age of death: adult

HPO:

64
malignant melanoma, somatic:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 155600
Disease Ontology11 DOID:1909, DOID:6846
MeSH39 D008545
NCIt45 C3224, C8498
ICD10 via Orphanet31 C43.5, C43.6, C43.7 C43.8, C43.0, C43.1, C43.2, C43.3, C43.4, D22.9, more
ICD1030 D03.9

Summaries for Malignant Melanoma, Somatic

About this section
OMIM:52 Malignant melanoma is a neoplasm of pigment-producing cells called melanocytes that occurs most often in the skin, but... (155600) more...

MalaCards based summary: Malignant Melanoma, Somatic, also known as melanoma, is related to clear cell sarcoma and melanoma, cutaneous malignant 8, and has symptoms including melanoma, dry skin and freckling. An important gene associated with Malignant Melanoma, Somatic is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways are Pathways in cancer and Glioma. The drugs interferon alfa-2b and procarbazine have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and lung, and related mouse phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Decreased cella89culturea89derived Hepatitis C virus (HCVcc.

Disease Ontology:11 A cell type cancer that has material basis in abnormally proliferating cells derived from melanocytes which are found in skin, the bowel and the eye.

MedlinePlus:38 Melanoma is the most serious type of skin cancer. often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. most melanomas have a black or black-blue area. melanoma may also appear as a new mole. it may be black, abnormal, or "ugly looking." thinking of "abcde" can help you remember what to watch for: asymmetry - the shape of one half does not match the other border - the edges are ragged, blurred or irregular color - the color is uneven and may include shades of black, brown and tan diameter - there is a change in size, usually an increase evolving - the mole has changed over the past few weeks or months surgery is the first treatment of all stages of melanoma. other treatments include chemotherapy and radiation, biologic, and targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

Related Diseases for Malignant Melanoma, Somatic

About this section

Diseases related to Malignant Melanoma, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 164)
idRelated DiseaseScoreTop Affiliating Genes
1clear cell sarcoma34.4CDK4, KIT, TP53
2melanoma, cutaneous malignant 834.0MITF, TYR
3dysplastic nevus syndrome12.5
4acral lentiginous melanoma12.2
5primary malignant melanoma of the cervix12.0
6balloon cell malignant melanoma12.0
7nodular malignant melanoma12.0
8dubin-johnson syndrome11.9BAP1, BRAF, CDK4, CDKN2A, CDKN2B, IFNA2
9pancreatic cancer/melanoma syndrome11.9
10rectum malignant melanoma11.8
11cdk4-related cutaneous malignant melanoma11.8
12cdkn2a-related cutaneous malignant melanoma11.8
13malignant melanoma, childhood11.8
14primary malignant melanoma of the conjunctiva11.8
15pot1-related susceptibility to cutaneous malignant melanoma11.8
16malignant melanoma of the mucosa11.8
17mirror movements 111.6
18brown-vialetto-van laere syndrome11.6CDK4, CDKN2A, KIT, MGMT, MITF, NRAS
19ciliary body spindle cell melanoma11.6BAP1, CDK4, CDKN2A, KIT, MC1R, MITF
20lung cancer11.6BRAF, CDK4, CDKN2A, CDKN2B, MGMT, NRAS
21melanoma, cutaneous malignant, 911.5
22melanoma, cutaneous malignant, 611.5
23melanoma, cutaneous malignant, 511.5
24learning disability11.5BRAF, CDKN2A, CDKN2B, MC1R, MITF, NRAS
25colorectal cancer11.5BRAF, CDK4, CDKN2A, IFNA2, MGMT, NRAS
26melanoma, cutaneous malignant, 211.5
27melanoma, cutaneous malignant, 311.5
28hepatocellular carcinoma11.5CDK4, CDKN2A, CDKN2B, IFNA2, KIT, PTEN
29heavy chain disease11.5CDKN2A, KIT, MC1R, MITF, NRAS, TP53
30skin melanoma11.5
31pancreatic cancer11.4
32hypersplenism11.4BRAF, CDKN2A, KIT, NRAS, PTEN, TERT
33penis carcinoma in situ11.4CDKN2A, CDKN2B, MC1R, MITF, TP53, TYR
34endodermal sinus tumor11.4BRAF, CDK4, CDKN2A, MC1R, MITF, PTEN
35intracranial structure hemangioma11.4KIT, MC1R, PTEN, TP53, TYR, TYRP1
36leukemia, acute myeloid11.4CDKN2A, CDKN2B, KIT, NRAS, TERT, TP53
37esophageal cancer11.4CDK4, CDKN2A, CDKN2B, PTEN, TERT, TP53
38parotid gland adenoid cystic carcinoma11.4BRAF, KIT, MITF, NRAS, TERT
39facial nerve disease11.4BAP1, CDKN2A, KIT, MC1R, NRAS
40prostate cancer, hereditary, x-linked 111.4BRAF, KIT, PTEN, STK11, TP53
41tumor predisposition syndrome11.4BAP1, CDKN2A, PTEN, STK11, TP53
42giant cell glioblastoma11.4CDK4, CDKN2A, MGMT, PTEN, TP53
43gliomatosis peritonei11.4CDK4, CDKN2A, MGMT, PTEN, TP53
44gliosarcoma11.4CDK4, CDKN2A, MGMT, PTEN, TP53
45mixed germ cell-sex cord neoplasm11.4BRAF, CDKN2A, CDKN2B, KIT, TP53
46karak syndrome11.3BRAF, CDK4, CDKN2A, PTEN
47asrar facharzt haque syndrome11.3CDK4, CDKN2A, CDKN2B, KIT
48vulvar sarcoma11.3CDKN2A, KIT, NRAS, TYR
49adenofibroma11.3CDK4, CDKN2A, NRAS, TP53
50early myoclonic encephalopathy11.3CDKN2A, MGMT, PTEN, TP53

Graphical network of the top 20 diseases related to Malignant Melanoma, Somatic:



Diseases related to malignant melanoma, somatic

Symptoms & Phenotypes for Malignant Melanoma, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

155600

Clinical features from OMIM:

155600

Human phenotypes related to Malignant Melanoma, Somatic:

 64 54 (show all 17)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 melanoma64 54 hallmark (90%) Very frequent (99-80%) HP:0002861
2 dry skin64 54 typical (50%) Frequent (79-30%) HP:0000958
3 freckling64 54 typical (50%) Frequent (79-30%) HP:0001480
4 abnormality of the lymphatic system64 54 typical (50%) Frequent (79-30%) HP:0100763
5 retinopathy64 54 occasional (7.5%) Occasional (29-5%) HP:0000488
6 abnormality of extrapyramidal motor function64 54 occasional (7.5%) Occasional (29-5%) HP:0002071
7 neoplasm of the pancreas64 54 occasional (7.5%) Occasional (29-5%) HP:0002894
8 neoplasm of the stomach64 54 occasional (7.5%) Occasional (29-5%) HP:0006753
9 neoplasm of the breast64 54 occasional (7.5%) Occasional (29-5%) HP:0100013
10 abnormality of the eye64 HP:0000478
11 numerous nevi64 HP:0001054
12 atypical nevus64 HP:0001062
13 atypical nevi in non-sun exposed areas64 HP:0001074
14 intraocular melanoma64 HP:0007716
15 cutaneous melanoma64 HP:0012056
16 abnormality of the hair54 Frequent (79-30%)
17 nevus54 Very frequent (99-80%)

UMLS symptoms related to Malignant Melanoma, Somatic:


exanthema, pruritus

GenomeRNAi Phenotypes related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-111.7BRAF, CDKN2A, PMEL, POT1, PTEN, STK11
2GR00234-A-211.3BRAF, CDK4, STK11
3GR00381-A-111.2CDKN2A, KIT, NRAS, POT1, TERF2IP
4GR00193-A-311.2BRAF, CDK4, KIT
5GR00250-A-310.9BAP1, BRAF, MGMT, POT1, TERF2IP, TP53

MGI Mouse Phenotypes related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

41 (show all 26)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538411.6BAP1, BRAF, CDK4, CDKN2A, CDKN2B, KIT
2MP:000200611.6BAP1, BRAF, CDK4, CDKN2A, CDKN2B, KIT
3MP:000537911.5BRAF, CDK4, CDKN2A, CDKN2B, KIT, MGMT
4MP:000538011.5BAP1, BRAF, CDK4, CDKN2A, KIT, MITF
5MP:000538911.5BRAF, CDK4, CDKN2A, CDKN2B, KIT, MITF
6MP:001077111.5BRAF, CDK4, CDKN2A, CDKN2B, KIT, MC1R
7MP:000301211.5BAP1, CDKN2A, CDKN2B, KIT, MC1R, MGMT
8MP:000118611.4BRAF, CDK4, CDKN2A, KIT, MC1R, MITF
9MP:001076811.4BAP1, BRAF, CDK4, CDKN2A, CDKN2B, KIT
10MP:000538711.4BAP1, BRAF, CDK4, CDKN2A, CDKN2B, KIT
11MP:000537711.3BRAF, KIT, MC1R, MITF, TP53, TYRP1
12MP:000539111.3BRAF, CDK4, CDKN2A, KIT, MITF, NRAS
13MP:000537011.3BRAF, CDK4, CDKN2A, KIT, NRAS, PTEN
14MP:000539711.3BAP1, BRAF, CDK4, CDKN2A, CDKN2B, KIT
15MP:000537811.3BAP1, BRAF, CDK4, CDKN2A, KIT, MC1R
16MP:000536911.3BAP1, BRAF, CDK4, CDKN2A, KIT, PTEN
17MP:000539011.3BRAF, CDKN2A, KIT, MITF, PTEN, TERT
18MP:000537611.3BAP1, BRAF, CDK4, CDKN2A, CDKN2B, KIT
19MP:000287311.2BRAF, CDK4, KIT, MITF, NRAS, PTEN
20MP:000538611.2BRAF, CDK4, CDKN2A, KIT, MC1R, MITF
21MP:000537111.2KIT, MC1R, MITF, NRAS, PTEN, TP53
22MP:000538211.1BRAF, KIT, MC1R, MITF, NRAS, STK11
23MP:000363111.1BRAF, CDK4, CDKN2A, KIT, MITF, PTEN
24MP:000536710.8BRAF, CDK4, CDKN2B, KIT, PTEN, STK11
25MP:000538510.8BAP1, BRAF, CDK4, CDKN2A, KIT, NRAS
26MP:000538110.6BRAF, CDK4, CDKN2A, KIT, NRAS, PTEN

Drugs & Therapeutics for Malignant Melanoma, Somatic

About this section

FDA approved drugs:

(show all 10)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Intron A16 44 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
2
Keytruda16 44 PEMBROLIZUMAB Merck September 2014
FDA Label: Keytruda
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:16 KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:14 1. Programmed cell death protein 1
Mechanism of Action:16 
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
3
Mekinist16 44 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
FDA Label: Mekinist
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Indications and Usage:16 MEKINIST is a kinase inhibitor indicated as a single agent and incombination with dabrafenib for the treatment of patients with unresectable ormetastatic melanoma with BRAF V600E or V600K mutations as detected byan FDA-approved test. The use in combination is based on the demonstrationof durable response rate. Improvement in disease-related symptoms or overallsurvival has not been demonstrated for MEKINIST in combination withdabrafenib. (1, 14.1)Limitation of use: MEKINIST as a single agent is not indicated for treatmentof patients who have received prior BRAF-inhibitor therapy. (1)
DrugBank Targets:14 1. Dual specificity mitogen-activated protein kinase kinase 1;2. Dual specificity mitogen-activated protein kinase kinase 2
Mechanism of Action:16 
Target: mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase
Action: inhibitor
FDA: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1(MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins areupstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotescellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAFpathway which includes MEK1 and MEK2. Trametinib inhibits BRAF V600 mutation-positivemelanoma cell growth in vitro and in vivo.Trametinib and dabrafenib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
4
Opdivo16 44 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma
Indications and Usage:16 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibodyindicated for the treatment of patients with: unresectable or metastatic melanoma and disease progression followingipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1)This indication is approved under accelerated approval based on tumorresponse rate and durability of response. Continued approval for thisindication may be contingent upon verification and description of clinicalbenefit in the confirmatory trials. (1.1, 14.1) metastatic squamous non-small cell lung cancer with progression on orafter platinum-based chemotherapy. (1.2)
DrugBank Targets:14 1. Programmed cell death protein 1
Mechanism of Action:16 
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibitsT-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in sometumors and signaling through this pathway can contribute to inhibition of active T-cell immunesurveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibodythat binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1pathway-mediated inhibition of the immune response, including the anti-tumor immuneresponse. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumorgrowth.
5
Proleukin16 44 ALDESLEUKIN Chiron January 1998
FDA Label: Proleukin
Disease/s that Drug Treats:Metastatic melanoma
Indications and Usage:16 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. See“CONTRAINDICATIONS”, “WARNINGS” and “PRECAUTIONS” sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See “CLINICAL PHARMACOLOGY” section,“CLINICAL STUDIES” section and “ADVERSE REACTIONS” section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:14 1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma
Mechanism of Action:16 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
6
Sylatron16 44 PEGINTERFERON ALFA-2B Merck April 2011
FDA Label: Sylatron
Disease/s that Drug Treats:melanoma
Indications and Usage:16 PegIntron is an antiviral indicated for treatment of Chronic Hepatitis C(CHC) in patients with compensated liver disease. (1.1)
DrugBank Targets:14 1. Interferon alpha/beta receptor 1;2. Interferon alpha/beta receptor 2
Mechanism of Action:16 
Target: innate antiviral immune response
Action: inducer
FDA: Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response [see Microbiology (12.4)].
7
Tafinlar16 44 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
FDA Label: Tafinlar
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E mutation
Indications and Usage:16  TAFINLAR is a kinase inhibitor indicated as a single agent for thetreatment of patients with unresectable or metastatic melanoma withBRAF V600E mutation as detected by an FDA-approved test. (1.1, 2.1) TAFINLAR in combination with trametinib is indicated for the treatmentof patients with unresectable or metastatic melanoma with BRAF V600Eor V600K mutations as detected by an FDA-approved test. The use incombination is based on the demonstration of durable response rate.Improvement in disease-related symptoms or overall survival has notbeen demonstrated for TAFINLAR in combination with trametinib. (1.2,2.1, 14.2)Limitation of Use: TAFINLAR is not indicated for treatment of patients withwild-type BRAF melanoma. (1.3, 5.2)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Serine/threonine-protein kinase SIK1;4. Serine/threonine-protein kinase Nek11;5. LIM domain kinase 1
Mechanism of Action:16 
Target: some mutated forms of BRAF kinases, wild-type BRAF and CRAF kinases
Action: inhibitor
FDA: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes,respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higherconcentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E,can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [seeIndications and Usage (1)]. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cellgrowth in vitro and in vivo.Dabrafenib and trametinib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
8
Yervoy16 44 IPILIMUMAB Bristol-Myers Squibb March 2011
FDA Label: Yervoy
Disease/s that Drug Treats:metastatic melanoma
Indications and Usage:16 YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blockingantibody indicated for the treatment of unresectable or metastaticmelanoma. (1)
DrugBank Targets:14 1. Cytotoxic T-lymphocyte protein 4
Mechanism of Action:16 
Target: CTLA-4
Action: blocker of interation with CD80/CD86
FDA: CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody thatbinds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockadeof CTLA-4 has been shown to augment T-cell activation and proliferation, including theactivation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signalingcan also reduce T-regulatory cell function, which may contribute to a general increase in T cellresponsiveness, including the anti-tumor immune response.
9
Zelboraf16 44 VEMURAFENIB Roche August of 2011
FDA Label: Zelboraf
Disease/s that Drug Treats:BRAF + melanoma
Indications and Usage:16 ZELBORAF® is a kinase inhibitor indicated for the treatment of patients withunresectable or metastatic melanoma with BRAF V600E mutation as detectedby an FDA-approved test. (1, 2.1)Limitation of Use: ZELBORAF is not indicated for treatment of patients withwild-type BRAF melanoma. (2.1, 5.2)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf
Mechanism of Action:16 
Target: some mutated forms of BRAF serinethreoninekinase
Action: inhibitor
FDA: Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serinethreoninekinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF,ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in theBRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cellproliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenibhas anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.
10
Opdivo16 NIVOLUMAB Bristol-Myers Squibb March 2015
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:16 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with: * unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.1, 14.1) * metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. (1.2)
DrugBank Targets:14 Programmed cell death protein 1
Mechanism of Action:16 
Target: PD-1 receptor
Action: blocks its interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.

Drugs for Malignant Melanoma, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 604)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 2, Phase 1500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
TrametinibapprovedPhase 4, Phase 3, Phase 2, Phase 1121871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
3
Sorafenibapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2692284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
4
Sirolimusapproved, investigationalPhase 4, Phase 1, Phase 2189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
5
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 1, Phase 2362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
6
EverolimusapprovedPhase 4, Phase 1, Phase 21896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
7
Imiquimodapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 113899011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
8
AldesleukinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 139785898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
9
RanibizumabapprovedPhase 4, Phase 2, Phase 3, Phase 1474347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
10
VindesineapprovedPhase 44559917-39-4, 53643-48-440839
Synonyms:
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
D06304
DAVA
DB00309
Desacetylvinblastine Amide Sulfate
Desacetylvinblastine amide
EINECS 258-682-2
Eldesine
Eldisine
 
HMS2090E15
HSDB 6961
LS-162145
Lilly 112531
MolPort-005-933-570
NSC-245467
STOCK1N-75293
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
Vindesine (USAN/INN)
Vindesine Sulfate
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesinum
Vindesinum [INN-Latin]
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
vindesine
11
Dacarbazineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 16744342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
12
Triamcinoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3482124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
13
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
14
nivolumabapprovedPhase 4, Phase 3, Phase 2, Phase 1326946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
15
Edetic Acidapproved, vet_approvedPhase 4, Phase 3, Phase 29560-00-4, 62-33-96049
Synonyms:
(ethylenedinitrilo)tetraacetic acid, ion(4−)
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcium Disodium Edetate (JAN)
Calcium Disodium Versenate
Calcium disodium versenate (TN)
 
EDT
EDTA
EDTA, ion(4-)
Edetate Calcium
Edetate calcium disodium (USP)
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
acide edetique
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
16
CitalopramapprovedPhase 450359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
17
OlaparibapprovedPhase 4, Phase 1126763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
18
Bortezomibapproved, investigationalPhase 4, Phase 2, Phase 1794179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
19
SomatostatinapprovedPhase 4, Phase 3, Phase 2, Phase 122938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
20
Dasatinibapproved, investigationalPhase 4, Phase 2, Phase 1281302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
21
Etanerceptapproved, investigationalPhase 4397185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
22
Ramucirumabapproved, investigationalPhase 4, Phase 2, Phase 174947687-13-0
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
23
Vorinostatapproved, investigationalPhase 4, Phase 2, Phase 1242149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
24
NicotineapprovedPhase 4105054-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
25
Vareniclineapproved, investigationalPhase 4269249296-44-45310966
Synonyms:
249296-44-4
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine
7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
AC1L55H0
AC1Q4W6H
AKOS005145561
AR-1H2911
CHEBI:430452
CHEMBL1396
CID170361
CP 526555
 
CP-526,555
Champix
Chantix
D08669
HSDB 7591
I14-1963
LS-187375
UNII-W6HS99O8ZO
Varenicline
Varenicline (INN)
Varenicline tartrate
varenicline
26
Aminolevulinic acidapprovedPhase 4, Phase 2157106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
27
PalbociclibapprovedPhase 4, Phase 1, Phase 2113571190-30-211431660, 5005498
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
 
EC-000.2350
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
S1116_Selleck
28
CeritinibapprovedPhase 4, Phase 2, Early Phase 1361032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib
29
BupropionapprovedPhase 431934841-39-9, 34911-55-2444
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
AMFEBUTAMONE HCl
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion Hcl
Bupropion SR
Bupropion [INN:BAN]
Bupropion hydrocloride
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
 
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
LS-122817
Lopac0_000166
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
Spectrum_001663
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
alpha-(tert-butylamino)-m-chloropropiophenone
amfebutamonum
bupropion
30
Technetium tc 99m sulfur colloidapprovedPhase 4, Early Phase 122
Synonyms:
 
Technetium 99m sulfur colloid
Technetium Tc-99m Sulfur Colloid
31
CrizotinibapprovedPhase 4, Phase 297877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
32
Gefitinibapproved, investigationalPhase 4351184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
33
Lapatinibapproved, investigational, Approved March 2007Phase 4, Phase 2296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
34Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 15498
35HormonesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113979
36Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112767
37RadiopharmaceuticalsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1485
38
LactitolPhase 4, Phase 1, Phase 2332585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
39Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112778
40Triamcinolone diacetatePhase 4, Phase 2, Phase 3482
41Antifungal AgentsPhase 4, Phase 1, Phase 23615
42Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
43Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13612
44Imatinib MesylatePhase 4, Phase 2, Phase 1594123596
45Antibiotics, AntitubercularPhase 4, Phase 1, Phase 26972
46Anti-Bacterial AgentsPhase 4, Phase 2, Phase 3, Phase 110884
47Anti-Retroviral AgentsPhase 4, Phase 3, Phase 2, Phase 13232
48Anti-HIV AgentsPhase 4, Phase 3, Phase 2, Phase 13100
49triamcinolone acetonidePhase 4, Phase 2, Phase 3482
50Triamcinolone hexacetonidePhase 4, Phase 2, Phase 3482

Interventional clinical trials:

(show top 50)    (show all 2073)
idNameStatusNCT IDPhase
1Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant MelanomaUnknown statusNCT00226473Phase 4
2Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyUnknown statusNCT00540930Phase 4
3Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal MelanomaCompletedNCT01253759Phase 4
4Can We Miss Pigmented Lesions in Psoriasis Patients?CompletedNCT01053819Phase 4
5Post-Operative Drainage Following Lymph Node DissectionCompletedNCT00324272Phase 4
6Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 TreatmentCompletedNCT00352885Phase 4
7A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node DissectionCompletedNCT02476357Phase 4
8Surgery Versus Radiosurgery to Treat Metastatic Brain TumorsCompletedNCT00075166Phase 4
9Effect of Topical Imiquimod on Lentigo MalignaCompletedNCT01161888Phase 4
10Characterization of the Melanoma-Specific Immune ResponseRecruitingNCT00368615Phase 4
11Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesRecruitingNCT02626065Phase 4
12Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll MelanomaRecruitingNCT02451488Phase 4
13Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing CreamRecruitingNCT02685592Phase 4
14Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerRecruitingNCT02287675Phase 4
15Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness TrialRecruitingNCT01871506Phase 4
16Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
17An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaActive, not recruitingNCT01898585Phase 4
18TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyActive, not recruitingNCT02379000Phase 4
19A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Active, not recruitingNCT02068196Phase 4
20Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaNot yet recruitingNCT02645149Phase 4
21HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic MelanomaTerminatedNCT01683188Phase 4
22HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4
23Assessment and Tracking of Long-term Alefacept SafetyTerminatedNCT00454701Phase 4
24Genetically-informed Therapies for Patients With Metastatic CancerWithdrawnNCT02000739Phase 4
25Modified Melanoma Vaccine for High Risk or Low Residual Disease PatientsUnknown statusNCT01861938Phase 2, Phase 3
26Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic MelanomaUnknown statusNCT00002767Phase 3
27Vaccine Therapy in Treating Patients With Primary Stage II MelanomaUnknown statusNCT00005052Phase 3
28High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III MelanomaUnknown statusNCT00002763Phase 3
29Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the LiverUnknown statusNCT00039234Phase 3
30Vaccine Therapy for Patients With Stage III MelanomaUnknown statusNCT00052130Phase 3
31Vaccine Therapy for Patients With Stage IV MelanomaUnknown statusNCT00052156Phase 3
32Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or MelanomaUnknown statusNCT00002455Phase 3
33Treatment Of Radiation Retinopathy TrialUnknown statusNCT00811200Phase 2, Phase 3
34Collaborative Ocular Melanoma Study (COMS)Unknown statusNCT00000124Phase 3
35Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTICUnknown statusNCT00779714Phase 3
36Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha InterferonUnknown statusNCT00226408Phase 3
37Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol GelUnknown statusNCT01272609Phase 3
3818F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in OncologyUnknown statusNCT00207298Phase 3
39MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3
40Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With MelanomaCompletedNCT00002882Phase 3
41Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)CompletedNCT00091572Phase 3
42Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
43Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic MelanomaCompletedNCT00003027Phase 3
44S0008: Chemotherapy Plus Biological Therapy in Treating Patients With MelanomaCompletedNCT00006237Phase 3
45Nordic Adjuvant IFN Melanoma TrialCompletedNCT01259934Phase 3
46Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV MelanomaCompletedNCT00039000Phase 3
47Multicenter Selective Lymphadenectomy Trial (MSLT)CompletedNCT00275496Phase 3
48Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent MelanomaCompletedNCT00002892Phase 3
49Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCompletedNCT00324155Phase 3
50Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the GroinCompletedNCT00003444Phase 3

Search NIH Clinical Center for Malignant Melanoma, Somatic

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: melanoma

Genetic Tests for Malignant Melanoma, Somatic

About this section

Genetic tests related to Malignant Melanoma, Somatic:

id Genetic test Affiliating Genes
1 Cutaneous Malignant Melanoma 127
2 Malignant Melanoma27
3 Melanoma27
4 Cutaneous Malignant Melanoma24 MC1R
5 Malignant Melanoma, Somatic24 BRAF, CDKN2A, KIT, NRAS, PTEN

Anatomical Context for Malignant Melanoma, Somatic

About this section

MalaCards organs/tissues related to Malignant Melanoma, Somatic:

36
Skin, Brain, Lung, Lymph node, T cells, Eye, Liver

Publications for Malignant Melanoma, Somatic

About this section

Variations for Malignant Melanoma, Somatic

About this section

Clinvar genetic disease variations for Malignant Melanoma, Somatic:

5
id Gene Variation Type Significance SNP ID Assembly Location
1BRAFNM_004333.4(BRAF): c.1799T> A (p.Val600Glu)SNVPathogenicrs113488022GRCh37Chr 7, 140453136: 140453136
2CDKN2ACDKN2A, 5-BP DUP, NT19duplicationPathogenicChr na, -1: -1
3STK11NM_000455.4(STK11): c.580G> T (p.Asp194Tyr)SNVPathogenicrs121913315GRCh37Chr 19, 1220487: 1220487
4STK11NM_000455.4(STK11): c.508C> T (p.Gln170Ter)SNVPathogenicrs121913323GRCh37Chr 19, 1220415: 1220415
5STK11NM_000455.4(STK11): c.145T> G (p.Tyr49Asp)SNVPathogenicrs137853080GRCh37Chr 19, 1207057: 1207057
6STK11NM_000455.4(STK11): c.403G> C (p.Gly135Arg)SNVPathogenicrs137853081GRCh37Chr 19, 1219351: 1219351
7CDKN2ANM_000077.4(CDKN2A): c.106dupG (p.Ala36Glyfs)duplicationPathogenicrs398123152GRCh37Chr 9, 21974721: 21974721
8CDKN2ANM_000077.4(CDKN2A): c.226_244del19 (p.Ala76Cysfs)deletionPathogenic, risk factorrs587776716GRCh37Chr 9, 21971114: 21971132
9CDKN2ANM_000077.4(CDKN2A): c.301G> T (p.Gly101Trp)SNVPathogenic, risk factorrs104894094GRCh37Chr 9, 21971057: 21971057

Cosmic variations for Malignant Melanoma, Somatic:

8 (show all 14)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1651647KITskin,eye,malignant melanoma,NSc.1459G>Ap.G487S11
2COSM141856CHRM3skin,ear,malignant melanoma,NSc.1741T>Ap.F581I10
3COSM5049808NF1skin,ear,malignant melanoma,NSc.3652C>Tp.Q1218*10
4COSM1125BRAFskin,ear,malignant melanoma,NSc.1790T>Ap.L597Q10
5COSM110485GRIN2Askin,ear,malignant melanoma,NSc.3217G>Ap.E1073K10
6COSM476BRAFskin,ear,malignant melanoma,NSc.1799T>Ap.V600E10
7COSM27639BRAFskin,ear,malignant melanoma,NSc.1780G>Ap.D594N10
8COSM478BRAFskin,ear,malignant melanoma,NSc.1801A>Gp.K601E10
9COSM109660GRIN2Askin,ear,malignant melanoma,NSc.4097C>Tp.P1366L10
10COSM106626GRIN2Askin,ear,malignant melanoma,NSc.1959G>Ap.M653I10
11COSM141892CNR1skin,ear,malignant melanoma,NSc.145C>Tp.P49S10
12COSM471BRAFskin,ear,malignant melanoma,NSc.1790T>Gp.L597R10
13COSM5049807NF1skin,ear,malignant melanoma,NSc.3097C>Tp.Q1033*10
14COSM580NRASskin,ear,malignant melanoma,NSc.181C>Ap.Q61K10

Copy number variations for Malignant Melanoma, Somatic from CNVD:

6 (show top 50)    (show all 1977)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137911146500000InsertionMelanoma
213897110070601041599AmplificationC1orf159Melanoma
3149681111600000148000000DeletionMelanoma
4150071111800000116100000AmplificationNRASCutaneous malignant melanoma
5150081111800000116100000GainNRASMelanoma
6153871115048600115061038GainNRASMelanoma
7187151147200000149200000AmpficationSETDB1Melanoma
820086115300000247249719InsertionMelanoma
92128179207217092303813GainCDK6Malignant melanoma
10245431182188599196365692AmplificationASPMMelanoma
11245441182188599196365692AmplificationATP6V1G3Melanoma
12245451182188599196365692AmplificationB3GALT2Melanoma
13245461182188599196365692AmplificationC1orf27Melanoma
14245471182188599196365692AmplificationC1orf53Melanoma
15245481182188599196365692AmplificationC1orf99Melanoma
16245491182188599196365692AmplificationCDC73Melanoma
17245501182188599196365692AmplificationCFHMelanoma
18245511182188599196365692AmplificationCFHR1Melanoma
19245521182188599196365692AmplificationCFHR2Melanoma
20245531182188599196365692AmplificationCFHR3Melanoma
21245541182188599196365692AmplificationCFHR4Melanoma
22245551182188599196365692AmplificationCFHR5Melanoma
23245561182188599196365692AmplificationCRB1Melanoma
24245571182188599196365692AmplificationDENND1BMelanoma
25245581182188599196365692AmplificationF13BMelanoma
26245591182188599196365692AmplificationFAM5CMelanoma
27245601182188599196365692AmplificationGLRX2Melanoma
28245611182188599196365692AmplificationHMCN1Melanoma
29245621182188599196365692AmplificationKCNT2Melanoma
30245631182188599196365692AmplificationLHX9Melanoma
31245641182188599196365692AmplificationNEK7Melanoma
32245651182188599196365692AmplificationOCLMMelanoma
33245661182188599196365692AmplificationPDCMelanoma
34245671182188599196365692AmplificationPLA2G4AMelanoma
35245681182188599196365692AmplificationPRG4Melanoma
36245691182188599196365692AmplificationPTGS2Melanoma
37245701182188599196365692AmplificationPTPRCMelanoma
38245711182188599196365692AmplificationRGS1Melanoma
39245721182188599196365692AmplificationRGS13Melanoma
40245731182188599196365692AmplificationRGS18Melanoma
41245741182188599196365692AmplificationRGS2Melanoma
42245751182188599196365692AmplificationRGS21Melanoma
43245761182188599196365692AmplificationTPRMelanoma
44245771182188599196365692AmplificationTROVE2Melanoma
45245781182188599196365692AmplificationUCHL5Melanoma
46245791182188599196365692AmplificationZBTB41Melanoma
47262381198304656198310281DeletionMelanoma
48291721228366540228914590LOHMelanoma
49292951230000046500000InsertionMelanoma
50292961230000046500000InsertionMelanoma

Expression for genes affiliated with Malignant Melanoma, Somatic

About this section
Search GEO for disease gene expression data for Malignant Melanoma, Somatic.

Pathways for genes affiliated with Malignant Melanoma, Somatic

About this section

Pathways related to Malignant Melanoma, Somatic according to KEGG:

34
id Name KEGG Source Accession
1Melanomahsa05218

Pathways related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
110.9BRAF, CDK4, CDKN2A, CDKN2B, KIT, MITF
2
Show member pathways
10.9BRAF, CDK4, CDKN2A, CDKN2B, MITF, NRAS
310.8BRAF, CDK4, CDKN2A, MGMT, NRAS, PTEN
410.8CDK4, IFNA2, KIT, NRAS, PTEN, STK11
5
Show member pathways
10.8CDK4, CDKN2A, MGMT, PTEN, STK11, TP53
610.8CDK4, CDKN2A, CDKN2B, NRAS, TERT, TP53
7
Show member pathways
10.7CDK4, CDKN2A, CDKN2B, POT1, TERF2IP, TP53
8
Show member pathways
10.7BRAF, CDKN2B, NRAS, PTEN, STK11
910.7BRAF, CDK4, PTEN, STK11, TP53
10
Show member pathways
10.7BRAF, KIT, NRAS, PTEN, TP53
11
Show member pathways
10.7BRAF, CDK4, CDKN2A, NRAS, TP53
1210.7BRAF, CDK4, CDKN2A, NRAS, TP53
1310.7CDK4, CDKN2B, PTEN, STK11, TP53
1410.7CDK4, CDKN2A, CDKN2B, NRAS, TP53
1510.7CDK4, CDKN2A, MGMT, TERF2IP, TP53
1610.7BRAF, CDKN2A, PTEN, TP53
17
Show member pathways
10.7BRAF, CDK4, PTEN, TP53
1810.7KIT, NRAS, PTEN, TP53
19
Show member pathways
10.7CDK4, CDKN2A, CDKN2B, TP53
2010.7CDK4, CDKN2A, CDKN2B, TP53
21
Show member pathways
10.7CDK4, CDKN2A, CDKN2B, TP53
2210.7CDK4, CDKN2B, PTEN, TP53
2310.7BRAF, IFNA2, NRAS, TP53
24
Show member pathways
10.6BRAF, KIT, NRAS
2510.6KIT, MC1R, MITF
2610.6BRAF, NRAS, TP53
2710.6CDK4, TERT, TP53
2810.6POT1, TERF2IP, TERT

GO Terms for genes affiliated with Malignant Melanoma, Somatic

About this section

Cellular components related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleoplasmGO:000565411.8BAP1, CDK4, CDKN2B, MGMT, MITF, POT1
2chromosome, telomeric regionGO:000078111.4POT1, TERF2IP, TERT
3nuclear telomere cap complexGO:000078311.4POT1, TERF2IP, TERT
4melanosome membraneGO:003316211.4TYR, TYRP1
5nucleusGO:000563411.3BAP1, BRAF, CDK4, CDKN2A, CDKN2B, MGMT
6telosomeGO:007018710.6POT1, TERF2IP

Biological processes related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1cell cycle arrestGO:000705011.4CDKN2A, CDKN2B, STK11, TP53
2negative regulation of apoptotic processGO:004306611.4BRAF, MGMT, PTEN, TERT, TP53
3melanin biosynthetic processGO:004243811.4MC1R, PMEL, TYR, TYRP1
4negative regulation of cell proliferationGO:000828511.3BAP1, CDKN2A, CDKN2B, PTEN, STK11, TP53
5melanocyte differentiationGO:003031811.3KIT, MITF, TYRP1
6myeloid progenitor cell differentiationGO:000231811.3BRAF, KIT
7developmental pigmentationGO:004806611.3KIT, PMEL
8establishment of protein localization to telomereGO:007020011.3POT1, TERT
9pigmentationGO:004347311.2KIT, MC1R, TYR, TYRP1
10negative regulation of telomerase activityGO:005197411.1POT1, TP53
11Ras protein signal transductionGO:000726511.0CDKN2A, NRAS, TP53
12regulation of axon regenerationGO:004867911.0BRAF, PTEN
13replicative senescenceGO:009039911.0CDKN2A, TERT, TP53
14telomere maintenance via telomeraseGO:000700410.6POT1, TERF2IP, TERT

Molecular functions related to Malignant Melanoma, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:000551511.7BAP1, BRAF, CDK4, CDKN2A, CDKN2B, IFNA2
2copper ion bindingGO:000550711.4TP53, TYR, TYRP1
3cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486111.4CDKN2A, CDKN2B
4G-rich strand telomeric DNA bindingGO:009850511.4POT1, TERF2IP
5telomeric DNA bindingGO:004216210.6POT1, TERF2IP, TERT

Sources for Malignant Melanoma, Somatic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet